{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=3BNC117", "query": { "intervention": "3BNC117" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 23, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=3BNC117&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-05T15:24:56.760Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03719664", "title": "Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "Albuvirtide", "type": "DRUG" }, { "name": "3BNC117", "type": "DRUG" }, { "name": "Baseline ART", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Frontier Biotechnologies Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2018-12-17", "completion_date": "2022-12", "has_results": false, "last_update_posted_date": "2021-09-29", "last_synced_at": "2026-09-05T15:24:56.760Z", "location_count": 7, "location_summary": "Palm Springs, California • San Francisco, California • Ft. Pierce, Florida + 4 more", "locations": [ { "city": "Palm Springs", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03719664" }, { "nct_id": "NCT02588586", "title": "A Study of the Safety and Antiretroviral Activity of 3BNC117", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "3BNC117", "type": "DRUG" }, { "name": "Antiretroviral Treatment Interruption", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Rockefeller University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 17, "start_date": "2015-10", "completion_date": "2018-04", "has_results": true, "last_update_posted_date": "2021-06-16", "last_synced_at": "2026-09-05T15:24:56.760Z", "location_count": 2, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02588586" }, { "nct_id": "NCT06071767", "title": "Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "ChAdOx1.tHIVconsv1", "type": "BIOLOGICAL" }, { "name": "ChAdOx1.HIVconsv62", "type": "BIOLOGICAL" }, { "name": "MVA.tHIVconsv3", "type": "BIOLOGICAL" }, { "name": "MVA.tHIVconsv4", "type": "BIOLOGICAL" }, { "name": "Vesatolimod (VES)", "type": "DRUG" }, { "name": "GS-5423", "type": "DRUG" }, { "name": "GS-2872", "type": "DRUG" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2024-04-01", "completion_date": "2029-08-01", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-09-05T15:24:56.760Z", "location_count": 9, "location_summary": "San Diego, California • Atlanta, Georgia • Chicago, Illinois + 6 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06071767" }, { "nct_id": "NCT04250636", "title": "3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Human Immunodeficiency Virus" ], "interventions": [ { "name": "3BNC117-LS", "type": "DRUG" }, { "name": "10-1074-LS", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rockefeller University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2020-10-13", "completion_date": "2022-02-11", "has_results": true, "last_update_posted_date": "2023-06-26", "last_synced_at": "2026-09-05T15:24:56.760Z", "location_count": 3, "location_summary": "New York, New York • Philadelphia, Pennsylvania", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04250636" }, { "nct_id": "NCT02825797", "title": "3BNC117 and 10-1074 in HIV-infected Individuals", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Human Immunodeficiency Virus (HIV)" ], "interventions": [ { "name": "3BNC117", "type": "DRUG" }, { "name": "10-1074", "type": "DRUG" }, { "name": "Analytical treatment interruption", "type": "OTHER" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Rockefeller University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 34, "start_date": "2016-06", "completion_date": "2018-08-15", "has_results": false, "last_update_posted_date": "2018-08-21", "last_synced_at": "2026-09-05T15:24:56.760Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02825797" }, { "nct_id": "NCT02850016", "title": "Romidepsin Plus 3BNC117 Phase 2a Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Human Immunodeficiency Virus (HIV)" ], "interventions": [ { "name": "3BNC117", "type": "DRUG" }, { "name": "Romidepsin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rockefeller University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 48, "start_date": "2017-01-06", "completion_date": "2020-12-31", "has_results": true, "last_update_posted_date": "2022-07-14", "last_synced_at": "2026-09-05T15:24:56.760Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02850016" }, { "nct_id": "NCT03254277", "title": "3BNC117-LS First-in-Human Phase 1 Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Human Immunodeficiency Virus" ], "interventions": [ { "name": "3BNC117-LS", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rockefeller University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 43, "start_date": "2017-09-13", "completion_date": "2020-12-31", "has_results": true, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-09-05T15:24:56.760Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03254277" }, { "nct_id": "NCT04560569", "title": "Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV/AIDS" ], "interventions": [ { "name": "Albuvirtide", "type": "DRUG" }, { "name": "3BNC117 Antibody", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Frontier Biotechnologies Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2021-11-30", "completion_date": "2022-12-01", "has_results": false, "last_update_posted_date": "2021-09-29", "last_synced_at": "2026-09-05T15:24:56.760Z", "location_count": 7, "location_summary": "Canoga Park, California • San Francisco, California • Hialeah, Florida + 4 more", "locations": [ { "city": "Canoga Park", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04560569" }, { "nct_id": "NCT04173819", "title": "Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "3BNC117-LS-J", "type": "BIOLOGICAL" }, { "name": "10-1074-LS-J", "type": "BIOLOGICAL" }, { "name": "Combination 3BNC117-LS-J and 10-1074-LS-J", "type": "BIOLOGICAL" }, { "name": "Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1", "type": "BIOLOGICAL" }, { "name": "Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2", "type": "BIOLOGICAL" }, { "name": "Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 3", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "International AIDS Vaccine Initiative", "sponsor_class": "NETWORK", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 225, "start_date": "2019-01-25", "completion_date": "2023-09-01", "has_results": false, "last_update_posted_date": "2025-05-06", "last_synced_at": "2026-09-05T15:24:56.760Z", "location_count": 3, "location_summary": "Boston, Massachusetts • New York, New York • Seattle, Washington", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04173819" }, { "nct_id": "NCT03571204", "title": "Combination Therapy With 3BNC117 and 10-1074 in HIV-Infected Individuals", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV" ], "interventions": [ { "name": "3BNC117 and 10-1074", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 27, "start_date": "2018-09-10", "completion_date": "2021-03-29", "has_results": true, "last_update_posted_date": "2022-02-09", "last_synced_at": "2026-09-05T15:24:56.760Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03571204" } ] }